Medtronic's diabetes unit, MiniMed, experienced a decline in its stock value on its trading debut.

Medtronic's diabetes business unit, MiniMed, is reportedly planning an Initial Public Offering (IPO) in the United States, aiming to raise $784 million.

Medtronic's diabetes unit, MiniMed, is reportedly seeking to raise up to $784 million through an initial public offering (IPO) in the U.S. market.

Medtronic has revised its earnings outlook for 2026 downwards, attributing the change to recent updates concerning its MiniMed products.

MiniMed, a subsidiary of Medtronic, has priced its initial public offering of $560 million at $20 per share.

Medtronic's diabetes unit, MiniMed, is reportedly seeking $784 million in its upcoming US Initial Public Offering.

Investors are evaluating whether to buy MMED stock following the recent initial public offering of MiniMed.

Medtronic's diabetes unit, MiniMed, is reportedly seeking a valuation of $7.9 billion as it prepares for a US initial public offering.